NASDAQ$MLAB
Mesa Laboratories Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Reported Fourth Quarter and Full Fiscal Year 2025 Results
Mesa Laboratories reported solid results for the fourth quarter of fiscal year 2025, with a 5.5% increase in total revenues and a significant increase in operating income. Core organic revenue growth was strong across all four divisions, and the company improved its balance sheet by reducing inventory and paying down debt.
- Total revenues increased by 5.5% to $62.1 million in the fourth quarter of FY25.
- Operating income increased by 100.5% to $1.5 million in the fourth quarter of FY25.
- Non-GAAP core organic revenues growth was 6.3% for the fourth quarter of FY25.
- The company generated $42.6 million of free cash flow in FY25, which was used primarily for debt reduction.
Headline financials
Revenue & EPS history
Mesa Labs · Revenue · Quarterly
$62.1M
Revenue by segment
Mesa Labs · $63.7M total across 4 segments · Q4 2026
- Sterilization and Disinfection Control$29.1M—45.7%
- Calibration Solutions$13.6M—21.3%
- Clinical Genomics$12.2M—19.1%
- Biopharmaceutical Development$8.85M—13.9%
Forward guidance
The company expects to continue reducing its past due backlog in the first two quarters of FY26. The impact of global tariffs is currently mitigated due to product switching barriers and a high recurring revenue mix, but the resolution of global trade is uncertain.
Tailwinds
- Expectation to continue reducing past due backlog during the first two quarters of FY26.
- Barriers to switching products in highly regulated applications.
- Revenue base with a high recurring service and consumables mix (~75% of revenues for FY25).
- Strong gross profit margin percentages.
- Opportunities to leverage deep customer relationships and compete with companies facing similar challenges.
Headwinds
- Uncertainty regarding the ultimate resolution of global trade and potential unwinding of global economic flows.
- Potential for the FDA to appeal the federal court ruling regarding restrictions on lab-developed tests.
- Need to further increase focus on organizational and operational resilience and adaptability depending on global trade resolution.
- Short-term impacts of increased tariffs, although mostly mitigated currently.
- Competition with companies facing many of the same challenges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
+0.1%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+26.6%
Q2 2023
Best reaction
-24.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q3 2026 | +8.7% | +15.9% | +8.8% | |
| Q2 2026 | +2.1% | +6.7% | +3.7% | |
| Q1 2026 | -24.9% | -16.0% | -15.9% | |
| Q4 2025 | -9.3% | -13.5% | -12.8% | |
| Q3 2025 | +2.5% | +10.3% | +3.2% | |
| Q2 2025 | -11.4% | -16.2% | -7.6% | |
| Q1 2025 | +5.8% | +11.8% | +13.4% | |
| Q4 2024 | +13.3% | +5.5% | -3.4% | |
| Q3 2024 | +2.0% | -0.2% | +18.9% | |
| Q2 2024 | +0.1% | -8.8% | +2.0% | |
| Q1 2024 | +8.0% | +10.3% | +11.4% | |
| Q4 2023 | -2.2% | -7.7% | -11.7% | |
| Q3 2023 | -7.4% | -8.6% | -13.5% | |
| Q2 2023 | +26.6% | +31.2% | +39.1% | |
| Q1 2023 | -5.5% | -10.7% | -23.5% | |
| Q4 2022 | -3.7% | -2.7% | -6.1% | |
| Q3 2022 | -3.9% | -2.0% | -5.8% | |
| Q2 2022 | +4.0% | +1.4% | -0.1% | |
| Q1 2022 | +0.4% | -1.4% | -3.8% | |
| Q4 2021 | +4.7% | +6.4% | +9.6% | |
| Q3 2021 | +0.9% | -0.4% | -5.2% | |
| Q2 2021 | -0.4% | +2.7% | +2.1% | |
| Q1 2021 | +2.0% | -1.5% | -1.4% | |
| Q4 2020 | -5.7% | -6.5% | -18.6% | |
| Q3 2020 | -7.2% | -2.4% | -13.9% | |
| Q2 2020 | -0.2% | -4.7% | +3.3% | |
| Q1 2020 | +6.6% | +7.0% | -7.3% | |
| Q4 2019 | -21.1% | -19.3% | -2.3% | |
| Q3 2019 | +0.6% | +3.4% | +2.2% | |
| Q2 2019 | +0.9% | +3.0% | +20.4% | |
| Q1 2019 | -2.7% | -0.3% | +3.5% | |
| Q4 2018 | +16.3% | +15.4% | +31.3% | |
| Q3 2018 | -5.1% | -14.2% | -8.0% | |
| Q2 2018 | -17.2% | -19.7% | -19.7% | |
| Q1 2018 | +5.2% | +1.6% | -2.5% | |
| Q4 2017 | -6.5% | -13.3% | -12.3% | |
| Q3 2017 | +6.4% | +1.4% | +5.2% | |
| Q2 2017 | -1.3% | -0.8% | -1.1% | |
| Q1 2017 | -4.3% | -10.4% | -10.5% | |
| Q4 2016 | +12.7% | +26.5% | +23.1% | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +1.9% | — | — | |
| Q1 2016 | +13.3% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +0.8% | — | — | |
| Q2 2015 | +10.4% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -4.0% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q3 2014 | -0.2% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | -0.2% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2011 | +1.5% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2010 | +0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro